Two-drug vs . three-drug combinations for HIV-1: Do we have enough data to make the switch?

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

(2018) Cristina Mussini et al.   BMC Medicine

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

(2018) L Ryom et al.   HIV MEDICINE

Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy

(2018) E Sezgin et al.   HIV MEDICINE

Brief Report

(2018) Jose R. Castillo-Mancilla et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

(2018) Simone Belmonti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART

(2018) Monica Gandhi et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial

(2018) Thomas A Rasmussen et al.   Lancet HIV

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Re-evaluating evolution in the HIV reservoir

(2017) Daniel I. S. Rosenbloom et al.   NATURE

Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus

(2017) Maria Raffaella Petrara et al.   PLoS One

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

(2017) Pedro Cahn et al.   Journal of the International AIDS Society

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation

(2017) Rajesh T. Gandhi et al.   PLoS Pathogens

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial

(2017) Ingeborg Wijting et al.   Lancet HIV

The effect of treatment simplification on HIV reservoirs

(2017) Gilles Darcis et al.   Lancet HIV

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

(2017) Fanny Chereau et al.   PLoS One

Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults

(2016) Mohammad-Ali Jenabian et al.   AIDS

Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia

(2016) Amélie Guihot et al.   AIDS

Update of Survival for Persons With HIV Infection in Denmark

(2016) Nicolai Lohse et al.   ANNALS OF INTERNAL MEDICINE

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

(2016) Alessandra Latini et al.   BMC INFECTIOUS DISEASES

Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression

(2016) Jose R. Castillo-Mancilla et al.   CLINICAL INFECTIOUS DISEASES

The role of tenofovir alafenamide in future HIV management

(2016) A Antela et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site

(2016) Yiying Huang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Persistent HIV-1 replication maintains the tissue reservoir during therapy

(2016) Ramon Lorenzo-Redondo et al.   NATURE

Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis

(2016) Narendran Gopalan et al.   AIDS Research and Therapy

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

(2016) Jean-Guy Baril et al.   PLoS One

Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy

(2015) M Younas et al.   HIV MEDICINE

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

(2015) José R Arribas et al.   LANCET INFECTIOUS DISEASES

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

(2015) José A Perez-Molina et al.   LANCET INFECTIOUS DISEASES

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy

(2015) Omar J. BenMarzouk-Hidalgo et al.   MEDICINE

Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment

(2014) Allan R. Tenorio et al.   JOURNAL OF INFECTIOUS DISEASES

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

(2014) Pedro Cahn et al.   LANCET INFECTIOUS DISEASES

The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis

(2014) Anna Odone et al.   PLoS One

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL

(2014) Andrea Antinori et al.   Journal of the International AIDS Society

Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation

(2014) Berta Torres et al.   Journal of the International AIDS Society

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality

(2014) Sergio Serrano-Villar et al.   PLoS Pathogens

HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene

(2013) Marjorie Pion et al.   AIDS

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study

(2013) R Weber et al.   HIV MEDICINE

Long-Term Suppressive Combined Antiretroviral Treatment Does Not Normalize the Serum Level of Soluble CD14

(2013) G. Mendez-Lagares et al.   JOURNAL OF INFECTIOUS DISEASES

Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial

(2013) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen

(2013) Clotilde Allavena et al.   JOURNAL OF MEDICAL VIROLOGY

Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers

(2013) Hiroyu Hatano et al.   PLoS Pathogens

Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients

(2012) Jean-Philippe Bastard et al.   ANTIVIRAL THERAPY

HIV-1 Antiretroviral Resistance

(2012) Michele W. Tang et al.   DRUGS

Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation

(2012) Sergio Reus et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The Expression of Cholesterol Metabolism Genes in Monocytes From HIV-Infected Subjects Suggests Intracellular Cholesterol Accumulation

(2012) Eoin R. Feeney et al.   JOURNAL OF INFECTIOUS DISEASES

Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells

(2012) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users

(2011) M. L. Salter et al.   CLINICAL INFECTIOUS DISEASES

Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy

(2011) Tae-Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies

(2010)   CLINICAL INFECTIOUS DISEASES

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

Inferior Clinical Outcome of the CD4+Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+Cell Counts and HIV RNA Levels during Follow‐up

(2008)   JOURNAL OF INFECTIOUS DISEASES

Human Immunodeficiency Virus (HIV)-1 Viral Protein R Suppresses Transcriptional Activity of Peroxisome Proliferator-Activated Receptor γ and Inhibits Adipocyte Differentiation: Implications for HIV-Associated Lipodystrophy

(2007) Shashi Shrivastav et al.   MOLECULAR ENDOCRINOLOGY